The Claim

In fibroblasts derived from human patients with cerebral creatine deficiency syndromes caused by creatine transporter (CRT) mutations, both cyclocreatine and creatine uptake are significantly reduced, indicating that impaired transporter function similarly affects the cellular uptake of both molecules.

Source: Cyclocreatine Transport by SLC6A8, the Creatine Transporter, in HEK293 Cells, a Human Blood-Brain Barrier Model Cell, and CCDSs Patient-Derived Fibroblasts

What the research says

Roughly balanced

Support and challenge are close. The picture may shift as more studies come in.

Supports

4score

Challenges

0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works

1 study reviewed

In plain English

In people with a rare brain disorder caused by a broken creatine transporter, their cells don't take in creatine or a similar molecule called cyclocreatine as well — showing the broken transporter affects both in the same way.

See the scientific wording

Cyclocreatine and creatine uptake are significantly reduced in fibroblasts derived from patients with cerebral creatine deficiency syndromes (CCDSs) due to CRT mutations, indicating impaired transporter function affects both molecules similarly in human cells.

What the research says

1 study

Study: Cyclocreatine Transport by SLC6A8, the Creatine Transporter, in HEK293 Cells, a Human Blood-Brain Barrier Model Cell, and CCDSs Patient-Derived Fibroblasts
The study found that both creatine and cyclocreatine don’t get into cells as well when the transporter is broken, which is exactly what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.